These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30685251)

  • 1. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
    Coelho CH; Gazzinelli-Guimaraes PH; Howard J; Barnafo E; Alani NAH; Muratova O; McCormack A; Kelnhofer E; Urban JF; Narum DL; Anderson C; Langhorne J; Nutman TB; Duffy PE
    Vaccine; 2019 Feb; 37(8):1038-1045. PubMed ID: 30685251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial.
    Sagara I; Healy SA; Assadou MH; Kone M; Swihart BJ; Kwan JL; Fintzi J; Sissoko K; Kamate B; Samake Y; Guindo MA; Doucoure M; Niaré K; Dolo A; Diarra B; Rausch KM; Narum DL; Jones DS; MacDonald NJ; Zhu D; Gorres JP; Imeru A; Mohan R; Thera I; Zaidi I; Salazar-Miralles F; Duan J; Neal J; Morrison RD; Muratova O; Sylla D; O'Connell EM; Wu Y; Hume JCC; Coulibaly MB; Anderson CF; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2023 Nov; 23(11):1266-1279. PubMed ID: 37499679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
    J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Scaria PV; Chen BB; Rowe CG; Alani N; Muratova OV; Barnafo EK; Lambert LE; Zaidi IU; Lees A; Rausch KM; Narum DL; Duffy PE
    Vaccine; 2020 Jul; 38(34):5480-5489. PubMed ID: 32600913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
    Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N
    Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
    Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
    Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.
    Espinosa DA; Vega-Rodriguez J; Flores-Garcia Y; Noe AR; Muñoz C; Coleman R; Bruck T; Haney K; Stevens A; Retallack D; Allen J; Vedvick TS; Fox CB; Reed SG; Howard RF; Salman AM; Janse CJ; Khan SM; Zavala F; Gutierrez GM
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
    Ellis RD; Wu Y; Martin LB; Shaffer D; Miura K; Aebig J; Orcutt A; Rausch K; Zhu D; Mogensen A; Fay MP; Narum DL; Long C; Miller L; Durbin AP
    PLoS One; 2012; 7(10):e46094. PubMed ID: 23056238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity.
    Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC
    Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice.
    Noland GS; Chowdhury DR; Urban JF; Zavala F; Kumar N
    Vaccine; 2010 Apr; 28(17):2917-23. PubMed ID: 20188676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
    Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
    Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
    Duncan CJ; Sheehy SH; Ewer KJ; Douglas AD; Collins KA; Halstead FD; Elias SC; Lillie PJ; Rausch K; Aebig J; Miura K; Edwards NJ; Poulton ID; Hunt-Cooke A; Porter DW; Thompson FM; Rowland R; Draper SJ; Gilbert SC; Fay MP; Long CA; Zhu D; Wu Y; Martin LB; Anderson CF; Lawrie AM; Hill AV; Ellis RD
    PLoS One; 2011; 6(7):e22271. PubMed ID: 21799809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.